Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19.

European journal of clinical pharmacology - 1 Apr 2012

Swen J J, van der Straaten T, Wessels J A M, Bouvy M L, Vlassak E E W, Assendelft W J J, Guchelaar H-J

Abstract excerpt

PURPOSE: Our purpose was to investigate the feasibility of pharmacy-initiated pharmacogenetic (PGt) screening in primary care with respect to patient willingness to participate, quality of DNA collection with saliva kits, genotyping, and dispensing data retrieved from the pharmacy. METHODS: Polypharmacy patients aged >60 years who used at least one drug with Anatomical Therapeutic Chemical (ATC) code...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Cytochrome P-450 CYP2D6

Share to Genetic Testing

Share to Saliva

Source

Open in PubMed Open full text

Identifiers

PMID: 21984116
DOI: 10.1007/s00228-011-1130-4
PMCID: PMC3303061

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19.PMID 21984116Read ↗

Availability of CYP2D6 genotyping results in general practitioner and community pharmacy medical records.Semantic proximity Read ↗

Clinical Guidelines for Psychiatrists for the Use of Pharmacogenetic Testing for CYP450 2D6 and CYP450 2C19Semantic proximity Read ↗

Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting.Semantic proximity Read ↗

Implementation of pharmacogenomic testing service through community pharmacy in the Netherlands: results from an early service evaluationSemantic proximity Read ↗

Feasibility of Community Pharmacist-Initiated and Point-of-Care CYP2C19 Genotype-Guided De-Escalation of Oral P2Y12 Inhibitors.Semantic proximity Read ↗

Design and Early Implementation Successes and Challenges of a Pharmacogenetics Consult ClinicSemantic proximity Read ↗

Towards the implementation ofCYP2D6andCYP2C19genotypes in clinical practice: Update and report from a pharmacogenetic service clinicSemantic proximity Read ↗

Pharmacotherapy Associated with CYP2C19, CYP2C9, CYP2D6, and UGT1A1 Genes in Population Sample: Observational Cross Sectional Analytical StudySemantic proximity Read ↗

Frequencies of CYP2C19 and CYP2D6 gene variants in a German inpatient sample with mood and anxiety disorders.Semantic proximity Read ↗

Prevalence and correlates of pharmacotherapy metabolized by CYP2C19, CYP2C9, CYP2D6, and UGT1A1 in the population sample.Semantic proximity Read ↗

Drug Use among Nursing Home Residents in Denmark for Drugs Having Pharmacogenomics Based (PGx) Dosing Guidelines: Potential for Preemptive PGx TestingSemantic proximity Read ↗

Utility and adoption of CYP2D6 and CYP2C19 genotyping and its translation into psychiatric clinical practice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.